DK1660100T3 - Anti-tumorformuleringer der omfatter defibrotid alene eller i kombination med andre anti-tumormidler - Google Patents

Anti-tumorformuleringer der omfatter defibrotid alene eller i kombination med andre anti-tumormidler

Info

Publication number
DK1660100T3
DK1660100T3 DK04764686T DK04764686T DK1660100T3 DK 1660100 T3 DK1660100 T3 DK 1660100T3 DK 04764686 T DK04764686 T DK 04764686T DK 04764686 T DK04764686 T DK 04764686T DK 1660100 T3 DK1660100 T3 DK 1660100T3
Authority
DK
Denmark
Prior art keywords
tumor
formulations
combination
defibrotide
agents
Prior art date
Application number
DK04764686T
Other languages
English (en)
Inventor
Laura Iris Ferro
Massimo Iacobelli
Paul Richardson
Original Assignee
Gentium Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentium Spa filed Critical Gentium Spa
Application granted granted Critical
Publication of DK1660100T3 publication Critical patent/DK1660100T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04764686T 2003-09-05 2004-08-27 Anti-tumorformuleringer der omfatter defibrotid alene eller i kombination med andre anti-tumormidler DK1660100T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001714A ITMI20031714A1 (it) 2003-09-05 2003-09-05 Formazioni ad azione antitumorale.
US53934404P 2004-01-28 2004-01-28
PCT/EP2004/009723 WO2005023273A1 (en) 2003-09-05 2004-08-27 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents

Publications (1)

Publication Number Publication Date
DK1660100T3 true DK1660100T3 (da) 2008-11-10

Family

ID=37064585

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04764686T DK1660100T3 (da) 2003-09-05 2004-08-27 Anti-tumorformuleringer der omfatter defibrotid alene eller i kombination med andre anti-tumormidler

Country Status (23)

Country Link
US (2) US8551967B2 (da)
EP (1) EP1660100B1 (da)
JP (1) JP4671962B2 (da)
KR (1) KR20060061367A (da)
CN (1) CN100490820C (da)
AT (1) ATE399558T1 (da)
AU (1) AU2004269896B2 (da)
BR (1) BRPI0414114A (da)
CA (1) CA2537226C (da)
DE (1) DE602004014787D1 (da)
DK (1) DK1660100T3 (da)
ES (1) ES2308223T3 (da)
IL (1) IL173785A0 (da)
IS (1) IS8334A (da)
IT (1) ITMI20031714A1 (da)
MX (1) MXPA06002489A (da)
NO (1) NO20061402L (da)
PT (1) PT1660100E (da)
RS (1) RS20060154A (da)
RU (1) RU2348413C2 (da)
UA (1) UA83500C2 (da)
WO (1) WO2005023273A1 (da)
ZA (1) ZA200601852B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070121001A (ko) * 2005-03-03 2007-12-26 젠티엄 에스피에이 신혈관 형성-의존성 종양 치료용 약학적 제제
EP1872787A1 (en) * 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP2103689A1 (en) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
JP6069209B2 (ja) 2010-11-12 2017-02-01 ジェンティウム ソシエタ ア レスポンサビリタ リミタータ 移植片対宿主病（ｇｖｈｄ）の予防および／または治療に使用するためのデフィブロタイド
RU2627177C2 (ru) 2012-06-22 2017-08-03 Джентиум С.Р.Л. Способ определения биологической активности дефибротида, основанный на применении эуглобулина
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
US10380734B2 (en) * 2017-02-27 2019-08-13 Aniket Bharat Parikh System, method and computer program product for security analysis of jewelry items
KR20200121780A (ko) * 2017-08-03 2020-10-26 재즈 파마슈티칼즈 아일랜드 리미티드 높은 농도에서 핵산을 포함하는 제제
KR20210008478A (ko) 2018-04-12 2021-01-22 재즈 파마슈티칼즈, 인코포레이티드 면역고갈과 관련된 사이토카인 방출 증후군 및 신경독성의 예방 및 치료를 위한 데피브로타이드
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
US20230190783A1 (en) 2020-02-28 2023-06-22 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899481A (en) * 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
DE2154279A1 (de) * 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
IT1043823B (it) * 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US4853221A (en) * 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) * 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) * 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) * 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US5977083A (en) * 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
IT1252174B (it) * 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
DE9202745U1 (da) 1992-03-02 1992-04-30 Howmedica Gmbh, 2314 Schoenkirchen, De
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
AU754242B2 (en) * 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
AU8125098A (en) 1997-05-30 1998-12-30 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6177545B1 (en) 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
DE19740384A1 (de) 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
KR100903243B1 (ko) * 1999-06-03 2009-06-17 제시 엘. 에스. 에이유 세포증식 및 세포사를 조절하기 위한 방법 및 조성물
EP1406930A4 (en) * 2000-12-29 2007-01-10 Savient Pharmaceuticals Inc "ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF"
US6770753B2 (en) 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
WO2003027313A2 (en) 2001-09-24 2003-04-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US20050032882A1 (en) * 2002-03-06 2005-02-10 Sophie Chen Botanical extract compositions and methods of use
CN1304011C (zh) * 2002-05-31 2007-03-14 雷根斯堡大学医学院 保护性寡聚脱氧核糖核苷酸的制药用途
CA2491363A1 (en) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
ES2378987T3 (es) 2002-08-06 2012-04-19 Toray Industries, Inc. Remedio o agente preventivo para una enfermedad renal y procedimiento para diagnosticar una enfermedad renal
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
KR20070121001A (ko) 2005-03-03 2007-12-26 젠티엄 에스피에이 신혈관 형성-의존성 종양 치료용 약학적 제제
EP1872787A1 (en) 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP1982722A1 (en) 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases

Also Published As

Publication number Publication date
ATE399558T1 (de) 2008-07-15
ZA200601852B (en) 2007-06-27
AU2004269896B2 (en) 2009-11-19
RS20060154A (en) 2008-08-07
IS8334A (is) 2006-02-28
JP4671962B2 (ja) 2011-04-20
RU2006109210A (ru) 2007-10-10
ES2308223T3 (es) 2008-12-01
CN100490820C (zh) 2009-05-27
EP1660100B1 (en) 2008-07-02
CA2537226C (en) 2016-05-03
CA2537226A1 (en) 2005-03-17
RU2348413C2 (ru) 2009-03-10
NO20061402L (no) 2006-03-28
PT1660100E (pt) 2008-10-14
DE602004014787D1 (de) 2008-08-14
US20140005256A1 (en) 2014-01-02
UA83500C2 (uk) 2008-07-25
US20060211646A1 (en) 2006-09-21
WO2005023273A1 (en) 2005-03-17
AU2004269896A1 (en) 2005-03-17
EP1660100A1 (en) 2006-05-31
KR20060061367A (ko) 2006-06-07
BRPI0414114A (pt) 2006-10-31
ITMI20031714A1 (it) 2005-03-06
JP2007504194A (ja) 2007-03-01
MXPA06002489A (es) 2006-06-20
US8551967B2 (en) 2013-10-08
IL173785A0 (en) 2006-07-05
CN1845746A (zh) 2006-10-11

Similar Documents

Publication Publication Date Title
NO20061402L (no) Anti-tumorformuleringer som omfatter defibrotid alene eller i kombinasjon med andre antitumormidler
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell&#39;epidermide
DE60045394D1 (de) Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
PT1411908E (pt) Tratamento de infeccoes da unha com no
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
NO20055722D0 (no) Antiseptiske preparater, fremgangsmater og systemer
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
ITMI20052171A1 (it) Composti e-amminocarbonil bicicloepten pirimidindiamminici stereoisomericamente arricchiti e loro uso
BRPI0516019A (pt) composições para o uso contra um ou mais agentes patogênicos
RS50510B (sr) Formulacije koje sadrže ekteinascidin i disaharid
GT200600520A (es) Agentes antibacterianos
ECSP066481A (es) Formulaciones que contienen cobre
HRP20090336T1 (en) Antitumor combinations containing vegf - trap and 5fu or one of its derivatives
NO20065791L (no) Asyklovir-formuleringer
ITMI20031396A1 (it) Composizione per uso farmaceutico o dietetico o cosmetico dotata di attivita&#39; antiossidante.
NO20052478D0 (no) Vitamin D-analoger, sammensetninger omfattende analogene og deres anvendelse.
ATE373504T1 (de) Avermectinen oder milbemycine und bis-aryl- derivate enthaltende anthelminthische zusammensetzungen
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
DE60321594D1 (de) Synergistische zusammensetzungen
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
BR0111785A (pt) Composições e métodos para tratamento de candidìase
TW200509794A (en) Novel anthelmintic and insecticidal compositions
MY141606A (en) N-alkoxyalkyl-substituted benzimidazoles, their preparation and their use as agents against parasitic protozoa
TR201900241T4 (tr) Vasoprotektif maddelerin kombinasyonları ve bunları içeren formülasyonlar.
WO2007081365A3 (en) Multiple antigenic agents and methods for using the same